Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy-Reference-Cited by-同舟云学术

Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

Published:2019-03-06 Issue:5 Volume:8 Page:e1574197
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Seban Romain-David¹^ORCID,Robert Charlotte²³⁴⁵,Dercle Laurent¹²⁶,Yeh Randy⁶,Dunant Ariane⁷,Reuze Sylvain²³⁴⁵,Schernberg Antoine⁴,Sun Roger²⁴,Mignot Fabien⁴,Terroir Marie¹,Schlumberger Martin¹³,Haie-Meder Christine⁴,Chargari Cyrus²⁴⁸⁹,Deutsch Eric²³⁴

Affiliation:

1. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France

2. INSERM, Villejuif, France

3. Faculté de médecine, Université Paris-Sud, Université Paris-Saclay, France

4. Department of Radiotherapy, Gustave Roussy, Université Paris-Saclay, Villejuif, France

5. Department of Medical Physics, Gustave Roussy, Université Paris-Saclay, Villejuif, France

6. Department of Radiology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA

7. Biostatistics and Epidemiology Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France

8. French Military Health Services Academy, Paris, France

9. Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1574197

Reference37 articles.

1. Tumor dose–volume response in image-guided adaptive brachytherapy for cervical cancer: A meta-regression analysis

2. [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy

3. Imaging in cervical cancer

4. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival

5. The Volume-metabolic Combined Parameters from 18F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast;British Journal of Radiology;2023-12-12

2. Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine;European Journal of Medical Research;2023-11-15

3. Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study;Frontiers in Immunology;2022-11-17

4. Prognostic Value of Bone Marrow Uptake Using 18F-FDG PET/CT Scans in Solid Neoplasms;Journal of Imaging;2022-10-31

5. Predicting treatment outcomes using ¹⁸F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy;Therapeutic Advances in Medical Oncology;2022-01